Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for sepsis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial 23921272 2013 09 24 2013 11 22 2016 11 25 1530-0293 41 10 2013 Oct Critical care medicine Crit. Care Med. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. 2336-43 10.1097/CCM.0b013e31828e969f We sought to evaluate whether procalcitonin was superior to C-reactive protein in guiding antibiotic therapy in intensive care patients with sepsis (...) . Randomized open clinical trial. Two university hospitals in Brazil. Patients with severe sepsis or septic shock. Patients were randomized in two groups: the procalcitonin group and the C-reactive protein group. Antibiotic therapy was discontinued following a protocol based on serum levels of these markers, according to the allocation group. The procalcitonin group was considered superior if the duration of antibiotic therapy was at least 25% shorter than in the C-reactive protein group. For both groups
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. BACKGROUND: Mortality from sepsis and septic shock remains high. Results of trials on intravenous immunoglobulins (IVIG) as adjunctive therapy for sepsis have been conflicting. This is an update of a Cochrane review that was originally published in 1999 and updated in 2002 and 2010. OBJECTIVES: To estimate the effects of IVIG as adjunctive therapy in patients with bacterial sepsis or septic shock on mortality (...) or no intervention in patients of any age with bacterial sepsis or septic shock. DATA COLLECTION AND ANALYSIS: Two authors independently assessed the studies for inclusion and undertook methodologic quality assessment and data abstraction. We conducted pre-specified subgroup analyses by type of immunoglobulin preparation. MAIN RESULTS: We included 43 studies that met our inclusion criteria in this updated review out of 88 potentially eligible studies. The studies included a large polyclonal IVIG trial
Single-Dose Etomidate Is Not Associated With Increased Mortality in ICU Patients With Sepsis: Analysis of a Large Electronic ICU Database PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?
Effect of Empirical Treatment With Moxifloxacin and Meropenem vs Meropenem on Sepsis-Related Organ Dysfunction in Patients With Severe Sepsis: A Randomized TrialTreatment for Sepsis-Related Organ Dysfunction PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?
The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta-analysis of randomized controlled trials The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta-analysis of randomized controlled trials The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta-analysis of randomized controlled trials Alhazzani W, Jacobi J, Sindi A, Hartog C, Reinhart K (...) , Kokkoris S, Gerlach H, Andrews P, Debrak T, Manzanares W, Cook DJ, Jaeschke RZ CRD summary This review found that selenium supplementation at doses higher than the daily requirement may reduce mortality in patients with sepsis. The low quality of the included trials and resulting potential for bias means that the reliability of the evidence is uncertain; however the authors’ cautious conclusions are appropriate. Authors' objectives To determine the efficacy of high-dose selenium for reducing mortality
[Diagnostic value of plasma soluble triggering receptor expressed on myeloid cells-1 for sepsis: a systematic review] Diagnostic value of plasma soluble triggering receptor expressed on myeloid cells-1 for sepsis: a systematic review Diagnostic value of plasma soluble triggering receptor expressed on myeloid cells-1 for sepsis: a systematic review Wu YP, Li JB, Deng XM Bibliographic details Wu YP, Li JB, Deng XM. Diagnostic value of plasma soluble triggering receptor expressed on myeloid cells (...) -1 for sepsis: a systematic review. Chinese Journal of Evidence-Based Medicine 2013; 13(4): 425-430 Indexing Status Subject indexing assigned by CRD MeSH Biomarkers; Humans; Membrane Glycoproteins; Receptors, Immunologic; Sepsis AccessionNumber 12013027880 Date abstract record published 07/06/2013 Record Status This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results
Late-Onset Sepsis in Very Low Birth Weight Infants from Singleton and Multiple-Gestation Births 23324523 2013 05 27 2013 08 06 2016 10 19 1097-6833 162 6 2013 Jun The Journal of pediatrics J. Pediatr. Late-onset sepsis in very low birth weight infants from singleton and multiple-gestation births. 1120-4, 1124.e1 10.1016/j.jpeds.2012.11.089 S0022-3476(12)01423-0 To describe and compare the incidence of late-onset sepsis (LOS) and demographic and clinical characteristics associated with LOS (...) epidemiology microbiology Infant, Very Low Birth Weight Logistic Models Male Multiple Birth Offspring Risk Factors Sepsis epidemiology microbiology NIHMS426675 PMC3633723 Stoll Barbara J BJ Fanaroff Avroy A AA Bell Edward F EF Duara Shahnaz S Goldberg Ronald N RN Laptook Abbot R AR Oh William W Shankaran Seetha S Walsh Michele C MC Das Abhik A Poole W Kenneth WK Wright Linda L LL Higgins Rosemary D RD Newman Nancy S NS Hale Ellen C EC Jobe Alan H AH Caplan Michael S MS Hensman Angelita M AM Fanaroff Avroy
De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. BACKGROUND: Mortality rates among patients with sepsis, severe sepsis or septic shock are highly variable throughout different regions or services and can be upwards of 50%. Empirical broad-spectrum antimicrobial treatment is aimed at achieving adequate antimicrobial therapy, thus reducing mortality; however, there is a risk that empirical broad-spectrum antimicrobial treatment can expose patients (...) to overuse of antimicrobials. De-escalation has been proposed as a strategy to replace empirical broad-spectrum antimicrobial treatment by using a narrower antimicrobial therapy. This is done by reviewing the patient's microbial culture results and then making changes to the pharmacological agent or discontinuing a pharmacological combination. OBJECTIVES: To evaluate the effectiveness and safety of de-escalation antimicrobial treatment for adult patients diagnosed with sepsis, severe sepsis or septic
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. IMPORTANCE: Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide (LPS) from binding at the cell surface MD2-TLR4 receptor. LPS is a major component of the outer membrane of gram-negative bacteria and is a potent activator of the acute inflammatory response. OBJECTIVE: To determine if eritoran, a TLR4 antagonist, would significantly reduce sepsis-induced (...) mortality. DESIGN, SETTING, AND PARTICIPANTS: We performed a randomized, double-blind, placebo-controlled, multinational phase 3 trial in 197 intensive care units. Patients were enrolled from June 2006 to September 2010 and final follow-up was completed in September 2011. INTERVENTIONS: Patients with severe sepsis (n = 1961) were randomized and treated within 12 hours of onset of first organ dysfunction in a 2:1 ratio with a 6-day course of either eritoran tetrasodium (105 mg total) or placebo, with n
Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis Haase N, Perner A, Inkeri (...) Hennings L, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J CRD summary This review concluded that the use of hydroxyethyl starch 130/0.38-0.45 in patients with sepsis increased use of renal replacement therapy, red blood cell transfusions and serious adverse events compared to human albumin or crystalloid. The authors' conclusions reflect the results of the review and appear likely to be reliable. Authors' objectives To assess the effects of fluid therapy with hydroxyethyl starch 130/0.38-0.45
Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Meta-analysis: intravenous immuno... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2007 ) Volume: 146 , Issue: 3 , Publisher: Am Coll Physicians , Pages: 193-203 PubMed: Available from or Find this paper at: Abstract BACKGROUND: Intravenous immunoglobulin therapy has been proposed as an adjuvant (...) treatment for sepsis. Yet, its benefit remains unclear, and its use is not currently recommended. PURPOSE: To evaluate the effect of polyclonal intravenous immunoglobulin therapy on death in critically ill adult patients with sepsis. DATA SOURCES: MEDLINE (1966 to May 2006) and the Cochrane Central Register of Controlled Trials (May 2006 edition). STUDY SELECTION: All randomized, controlled trials of critically ill adult patients with sepsis, severe sepsis, or septic shock who received polyclonal
High-volume haemofiltration for sepsis. BACKGROUND: Severe sepsis and septic shock are leading causes of death in the intensive care unit (ICU). This is despite advances in the management of patients with severe sepsis and septic shock including early recognition, source control, timely and appropriate administration of antimicrobial agents, and goal directed haemodynamic, ventilatory and metabolic therapies. High-volume haemofiltration (HVHF) is a blood purification technique which may improve (...) outcomes in critically ill patients with severe sepsis or septic shock. The technique of HVHF has evolved from renal replacement therapies used to treat acute kidney injury (AKI) in critically ill patients in the ICU. OBJECTIVES: This review assessed whether HVHF improves clinical outcome in adult critically ill patients with sepsis in an ICU setting. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2011, Issue 7); MEDLINE (1990 to August
Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis Wacker C, Prkno A, Brunkhorst FM, Schlattmann P CRD summary The review concluded that procalcitonin is a helpful biomarker for early diagnosis of sepsis in critically ill patients but that test results must be interpreted carefully (...) in the context of further medical information. These conclusions and the accompanying research recommendations are suitably cautious and appear likely to be reliable. Authors' objectives To assess the accuracy and clinical value of procalcitonin for diagnosing sepsis in critically ill patients. Searching Seven databases (including MEDLINE, EMBASE and The Cochrane Library) were searched from inception to February 2012 for studies in English, German or French; search terms were reported. Reference lists
In Patients With Severe Sepsis, Does a Single Dose of Etomidate to Facilitate Intubation Increase Mortality? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.